CRISPR Therapeutics AG (NASDAQ:CRSP) is considered one of the best short squeeze stocks to buy right now, with a Market Outperform rating and $86 price target from Citizens. Positive findings were discussed from CRISPR’s American Heart Association presentation on CTX310, targeting ANGPTL3 for cholesterol issues.

Citizens expressed optimism post-weekend data presentation, emphasizing major catalysts like in-vivo cardiovascular updates and pediatric reviews at upcoming medical meetings. CRISPR’s third-quarter Casgevy sales fell short of forecasts at $17 million, but the company remains confident in the product’s potential.

CRISPR Therapeutics AG (NASDAQ:CRSP) leads in gene-editing technology, focusing on precise treatments for diseases requiring DNA modifications. Despite its potential as an investment, other AI stocks may offer greater upside potential and lower downside risk. An undervalued AI stock report is available for those seeking investment opportunities.

For more stock insights, check out the 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds on Insider Monkey’s website. No disclosures were made in the article.

Read more at Yahoo Finance: Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown